Preference-Based EQ-5D index scores for chronic conditions in the United States
about
Ayurvedic herbal preparations for hypercholesterolaemiaCost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroidsThe appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysisUS valuation of health outcomes measured using the PROMIS-29.Burden of allergic respiratory disease: a systematic reviewCost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulinCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersCost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillationCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesElectrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness AnalysisThe Health Impact of Adult Cervical Deformity in Patients Presenting for Surgical Treatment: Comparison to United States Population Norms and Chronic Disease States Based on the EuroQuol-5 Dimensions Questionnaire.Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada.Cost-effectiveness of insulin analogues for diabetes mellitus.EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre.Reimbursement agency requirements for health related quality-of-life data: a case study.Health-related quality of life and socioeconomic status: inequalities among adults with a chronic diseaseCost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditionsHealth-related quality of life, and its determinants, among older people in rural Vietnam.Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus.Benchmarking health-related quality-of-life data from a clinical settingPersonality and EQ-5D scores among individuals with chronic conditions.Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasisUsing models to predict the future: what to do when the data run out?Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillationThe impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective.Application of minimal important differences in degenerative knee disease outcomes: a systematic review and case study to inform BMJ Rapid Recommendations.Measuring preferences for cost-utility analysis: how choice of method may influence decision-makingActive surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.Validity of LupusQoL-China for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosusA standardized vascular disease health check in europe: a cost-effectiveness analysis.An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study.An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea.Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients.Effect of age on cost-effectiveness of unicompartmental knee arthroplasty compared with total knee arthroplasty in the U.S.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR TrialDabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysesAcute and chronic impact of cardiovascular events on health state utilities.
P2860
Q24186216-D35A0451-9AD2-413A-8E86-8196A5044B73Q24657717-E410FF00-8BCC-45F0-8008-8346406D881CQ27021201-B969379F-AC94-40CF-AEC0-C0E8B371AEDAQ27308886-E2DB7861-407E-4CA9-BC1A-D486C75F6B19Q28079329-A4D7AD64-3A94-4099-9FC6-3B3C5F7DFFACQ28268410-E2E6497C-B385-412C-94B8-BEF8660431EDQ28483820-32F11352-ECB0-4B1C-99FE-27A351A33F29Q28484289-2F4F1243-C48A-4944-82A6-CE77C27AA7BCQ28488762-8187615F-CA4F-4E2D-BA94-3E28CCF98B1AQ28548272-2620DDAD-8DFC-4F11-8B8F-B30E8DEB9B3CQ30252746-5E614F96-C40C-4645-A835-7F55F2499359Q30278856-F78D07BC-DCF0-48F5-B5A0-9DCC38D90484Q30485897-D15B169B-FE43-4B9B-BDD5-D8D21659709BQ31124402-2D9AFF4C-CC9F-41B7-97CB-502361CD5382Q33516705-612CD510-74B4-4066-9222-0EECE3D1B4F6Q33573045-19133104-6C88-448E-B215-BCF31563A7A1Q33629561-9ED76ADF-4D2B-4D3B-8E8E-A460D741A180Q33653451-857CC761-EC33-49EC-90BC-BD2D143E3ACBQ33690073-6F149A4C-F325-4382-8D7F-08F927A0C33DQ33707239-685115EB-6253-49F0-80BB-A0CF27F00A4BQ33918024-6D64CE15-AE9C-42D8-AB2F-0B935882D467Q33950572-DF0F6D99-DD7A-4D13-941C-DE2A1A9290ADQ34098870-ABDBB365-9C14-4056-81F0-BF07093925A7Q34194956-09354538-7A19-484C-9AEB-28817A1A9BDCQ34237664-E7288D8B-768A-4EF3-BC1E-D1FB28CC68E8Q34321590-F69BB8A1-49B2-440D-8084-A6AF35D80F0AQ34371413-162EF9A5-7C84-46B5-8B6C-F82CB5C14D46Q34556585-E6ABB3BF-9C18-4156-B694-DD00B61E8168Q34614168-446580A5-D78A-48F3-B40D-4136BDC8C5BDQ34659767-A5CCEA75-E1ED-402F-BEE2-16524A0B6E5FQ34744620-98C46209-5B8C-41B4-A6AF-BEBA9443C554Q34837441-C6D78540-0069-42C7-A37A-8F060C79889FQ34899334-CAF36957-B04B-4C22-94F6-0E017160E6F8Q34995601-7029E61C-EEFE-44DE-9FF6-50ABB6622D72Q35100438-01AE6A73-8309-433B-A5D0-286A45171FACQ35131433-D4483406-0246-4AD6-8996-D6DEC66A5256Q35234175-331D7322-ED1F-4AA9-8B6C-91CF28A19202Q35478368-766F884E-4AF6-436B-A463-D06FDCE93128Q35485247-E6E4096D-8E09-4C1E-AF69-8C79047174DCQ35534337-74CEF081-9D59-4EE1-B2A2-F47B8B4BE2D7
P2860
Preference-Based EQ-5D index scores for chronic conditions in the United States
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Preference-Based EQ-5D index scores for chronic conditions in the United States
@ast
Preference-Based EQ-5D index scores for chronic conditions in the United States
@en
type
label
Preference-Based EQ-5D index scores for chronic conditions in the United States
@ast
Preference-Based EQ-5D index scores for chronic conditions in the United States
@en
prefLabel
Preference-Based EQ-5D index scores for chronic conditions in the United States
@ast
Preference-Based EQ-5D index scores for chronic conditions in the United States
@en
P2860
P356
P1476
Preference-Based EQ-5D index scores for chronic conditions in the United States
@en
P2093
Patrick W Sullivan
Vahram Ghushchyan
P2860
P304
P356
10.1177/0272989X06290495
P577
2006-07-01T00:00:00Z